Platform|API|Archive|Contact

Humanexa SignalsPharmaceutical Intelligence

FDA
EMA
MHRA
PMDA
Health Canada

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Pricing
Access
Commercial
Launch Tracking

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

Regulatory
Clinical
Competitive
Markets
M&A Watch
Strategy
Catalyst Tracker

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Asset / Drug

Rigshospitalet

Drug and asset intelligence for Rigshospitalet with 8 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 4
Catalysts: 4
Stage: Development stage unavailable

Recent signals(4)

ClinicalJuly 17, 2026

DETECT Study Aims to Identify Asymptomatic Atherosclerosis Prevalence and Risk Factors

The DETECT study aims to determine the prevalence of silent atherosclerosis in adults and identify risk factors for subclinical atherosclerosis.

ClinicalJuly 5, 2026

Study on Intraoperative Chest Tube Removal in Thoracoscopic Wedge Resection

The study investigates the safety and feasibility of intraoperative chest tube removal during thoracoscopic wedge resection.

ClinicalJuly 5, 2026

Study Evaluates AI's Impact on Clinician Confidence in Preterm Birth Risk Assessment

A randomized study is assessing how AI presentation formats affect clinicians' confidence and decision-making accuracy in obstetrics.

ClinicalJuly 4, 2026

Study on LSD's Effect on Serotonin 2A Receptor Occupancy Initiated

A study is underway to quantify the relationship between LSD dosage, plasma levels, and serotonin 2A receptor occupancy.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts(4)

Topline Data

— Rigshospitalet

July 17, 2026 · N/A

Topline Data

— Rigshospitalet

July 5, 2026 · N/A

Topline Data

— Rigshospitalet

July 5, 2026 · N/A

Topline Data

— Rigshospitalet

July 4, 2026 · N/A

Indications

No related entities indexed yet.

Therapeutic areas

AI Decision Support →

Atherosclerosis →

Cardiovascular →

Cardiovascular · Atherosclerosis →

Neurology · Psychotropic Agents →

Obstetrics · AI Decision Support →

Psychotropic Agents →

Surgery · Thoracic →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.